Teva Pharmaceutical Industries Ltd (NYSE: TEVA)

Teva Pharmaceutical Industries Ltd., or TEVA, is a global pharmaceutical company that specializes in the generic, innovative, and biopharmaceutical markets. Established in Israel in 1944, TEVA has grown to become a prominent player in the pharmaceutical industry with a mission to provide affordable medicines and innovative health solutions to patients worldwide.

The company is organized into three segments: North America, Europe, and International Markets. The North America segment includes the United States and Canada, while the Europe segment includes the European Union, the United Kingdom, and other European countries. The International Markets segment covers over 35 countries, making up a significant portion of the global pharmaceutical industry.

TEVA's primary products include generic medicines, biopharmaceuticals, innovative medicines, over-the-counter (OTC) products, and active pharmaceutical ingredients (APIs). TEVA's generic medicines business is committed to delivering high-quality and affordable medicines to patients, with a portfolio of over 500 generic prescription products in more than 1,400 dosage strengths, packaging sizes, and forms. The company's innovative medicines portfolio includes products such as AUSTEDO, AJOVY, UZEDY, and COPAXONE. AUSTEDO is a deuterated form of a small molecule inhibitor of vesicular monoamine 2 transporter (VMAT2) that regulates the levels of dopamine in the brain. AJOVY is a fully humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and is used for the preventive treatment of migraine in adults. UZEDY is a subcutaneous, long-acting formulation of risperidone that controls the steady release of risperidone. COPAXONE is a glatiramer acetate injection used for the treatment of patients with relapsing forms of multiple sclerosis (MS).

TEVA's biopharmaceuticals business focuses on developing and commercializing biosimilars, which are highly similar to the reference biologic in both structure and function. The company has launched several biosimilars, including Truxima, Herzuma, and Ranivisio. TEVA's OTC products business is focused on developing and commercializing a range of OTC products, such as SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA. TEVA's APIs business focuses on developing and commercializing a range of APIs, which are used as active ingredients in the manufacture of pharmaceutical products.

TEVA's competitive advantages include its global presence, diversified product portfolio, and strong pipeline of innovative medicines and biosimilars. The company's position in the generics market is supported by its global R&D function, as well as its API R&D and manufacturing activities, which provide significant vertical integration for its products. TEVA is one of the leading generic pharmaceutical companies in the world, with a strong presence in the United States, Europe, and other regions. The company is also a significant player in the innovative medicines market, with a portfolio of products that includes AUSTEDO, AJOVY, UZEDY, and COPAXONE.

TEVA's customers include retail pharmacies, hospital pharmacies, wholesalers, and distributors. The company's products are used by patients and healthcare professionals around the world and are available in a range of formulations and strengths.